Try our beta test site

Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: July 11, 2001
Last updated: April 28, 2015
Last verified: April 2003

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of combining oxaliplatin with capecitabine in treating patients who have colorectal, appendix, or small bowel cancer.

Condition Intervention Phase
Carcinoma of the Appendix
Colorectal Cancer
Small Intestine Cancer
Drug: capecitabine
Drug: oxaliplatin
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Pilot Study of Oxaliplatin in Combination With Capecitabine in Adult Cancer Patients

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: July 1999
Detailed Description:


  • Determine the maximum tolerated dose (MTD) of capecitabine when administered with oxaliplatin in patients with colorectal, appendiceal, or small bowel cancer.
  • Determine the clinical toxic effects associated with this regimen in these patients.
  • Characterize the molecular profile of tumor tissue obtained prior to study entry for determinants of sensitivity to this regimen in this patient population.
  • Characterize the molecular profile of a surrogate normal tissue (bone marrow aspirate) obtained prior to treatment and assess any potential drug-associated induction of DNA damage and inhibition of thymidylate synthase with a repeat bone marrow aspirate during therapy.
  • Assess any clinical activity of this regimen in this patient population.

OUTLINE: This is a dose-escalation study of capecitabine.

Patients receive oxaliplatin IV over 2 hours on day 1 followed by oral capecitabine twice daily on days 1-5 and 8-12. Courses repeat every 3 weeks in the absence of unacceptable toxicity or disease progression.

Cohorts of 3-6 patients receive escalating doses of capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients are followed every 3 months for 6 months.

PROJECTED ACCRUAL: A total of 106 patients will be accrued for this study within 36 months.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed colorectal, appendiceal, or small bowel cancer
  • Measurable disease
  • No progression after prior capecitabine
  • No brain metastases or leptomeningeal carcinomatosis



  • 18 and over

Performance status:

  • ECOG 0-2

Life expectancy:

  • Not specified


  • WBC at least 3,000/mm^3
  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3


  • Bilirubin normal
  • AST/ALT no greater than 2.5 times upper limit of normal


  • Creatinine normal
  • Creatinine clearance greater than 60 mL/min


  • No symptomatic congestive heart failure
  • No unstable angina pectoris
  • No cardiac arrhythmia


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No sensory neuropathy
  • No history of allergy to platinum compounds
  • No history of allergy to antiemetics appropriate for administration during study
  • No history of intolerance to fluorouracil
  • No uncontrolled concurrent illness that would preclude study entry
  • No ongoing or active infection requiring IV antibiotics
  • HIV negative


Biologic therapy:

  • At least 4 weeks since prior immunotherapy and recovered


  • See Disease Characteristics
  • Recovered from prior chemotherapy
  • No more than 2 prior systemic chemotherapy regimens for metastatic disease
  • At least 6 weeks since prior nitrosoureas or mitomycin
  • At least 8 weeks since prior eniluracil
  • At least 3 months since prior suramin
  • At least 4 weeks since other prior chemotherapy

Endocrine therapy:

  • Not specified


  • Recovered from prior radiotherapy
  • At least 2 weeks since prior radiotherapy to no more than 20% of bone marrow reserve
  • At least 4 weeks since prior radiotherapy to at least 21% of bone marrow reserve


  • Recovered from prior surgery


  • At least 4 weeks since prior sorivudine or brivudine and recovered
  • No concurrent sorivudine or brivudine
  • No other concurrent investigational agents
  • No other concurrent anticancer therapy or commercial agents
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00019773

United States, Maryland
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
Bethesda, Maryland, United States, 20892-1182
Sponsors and Collaborators
National Cancer Institute (NCI)
Study Chair: Eva Szabo, MD National Cancer Institute (NCI)
  More Information

Leonard G, Wright M, Quinn M, et al.: Survey of oxaliplatin-associated neurotoxicity with an interview-based questionnaire. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-3018, 2003.
Thomas R, Quinn M, Wilson R, et al.: A phase I trial of capecitabine (CAPE) & oxaliplatin (OHP). [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-530, 2001. Identifier: NCT00019773     History of Changes
Obsolete Identifiers: NCT00001817
Other Study ID Numbers: CDR0000067201
Study First Received: July 11, 2001
Last Updated: April 28, 2015

Keywords provided by National Cancer Institute (NCI):
stage I colon cancer
stage II colon cancer
stage III colon cancer
stage IV colon cancer
stage 0 colon cancer
stage 0 rectal cancer
stage I rectal cancer
stage II rectal cancer
stage III rectal cancer
stage IV rectal cancer
recurrent colon cancer
recurrent rectal cancer
small intestine adenocarcinoma
small intestine lymphoma
small intestine leiomyosarcoma
recurrent small intestine cancer
carcinoma of the appendix

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Appendiceal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Cecal Neoplasms
Cecal Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents processed this record on March 29, 2017